155 related articles for article (PubMed ID: 2555366)
1. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).
Moore MD; DiScipio RG; Cooper NR; Nemerow GR
J Biol Chem; 1989 Dec; 264(34):20576-82. PubMed ID: 2555366
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
3. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
Martin DR; Yuryev A; Kalli KR; Fearon DT; Ahearn JM
J Exp Med; 1991 Dec; 174(6):1299-311. PubMed ID: 1660522
[TBL] [Abstract][Full Text] [Related]
4. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
[TBL] [Abstract][Full Text] [Related]
5. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.
Lowell CA; Klickstein LB; Carter RH; Mitchell JA; Fearon DT; Ahearn JM
J Exp Med; 1989 Dec; 170(6):1931-46. PubMed ID: 2479703
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
[TBL] [Abstract][Full Text] [Related]
7. CR2 complement receptor.
Cooper NR; Bradt BM; Rhim JS; Nemerow GR
J Invest Dermatol; 1990 Jun; 94(6 Suppl):112S-117S. PubMed ID: 2161885
[TBL] [Abstract][Full Text] [Related]
8. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
9. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.
Tanner J; Weis J; Fearon D; Whang Y; Kieff E
Cell; 1987 Jul; 50(2):203-13. PubMed ID: 3036369
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
Barel M; Fiandino A; Lyamani F; Frade R
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
[TBL] [Abstract][Full Text] [Related]
12. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
Nemerow GR; Houghten RA; Moore MD; Cooper NR
Cell; 1989 Feb; 56(3):369-77. PubMed ID: 2464439
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
[TBL] [Abstract][Full Text] [Related]
15. Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.
Badar A; DeFreitas S; McDonnell JM; Yahya N; Thakor D; Razavi R; Smith R; Sacks S; Mullen GE
PLoS One; 2011 Apr; 6(4):e18275. PubMed ID: 21494666
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
[TBL] [Abstract][Full Text] [Related]
18. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
19. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
20. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
Weis JJ; Toothaker LE; Smith JA; Weis JH; Fearon DT
J Exp Med; 1988 Mar; 167(3):1047-66. PubMed ID: 2832506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
